304
Seres Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
195
FY23:
175
FY24:
38.7
FY25:
49.4
(positive)
Change from FY21 to FY25
millions USD
FY21:
51.2
FY22:
154
FY23:
183
FY24:
101
FY25:
88.8
Total assets
Change from FY21 to FY25
millions USD
FY21:
355
FY22:
349
FY23:
359
FY24:
140
FY25:
138
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
82.3
FY22:
85.6
FY23:
98.7
FY24:
41.2
FY25:
19.3
(negative)
Change from FY21 to FY25
millions USD
FY21:
141
FY22:
252
FY23:
305
FY24:
84.8
FY25:
74.7
(positive)
Change from FY21 to FY25
millions USD
FY21:
132
FY22:
10.8
FY23:
−44.9
FY24:
13.8
FY25:
44.2
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
355
FY22:
349
FY23:
359
FY24:
140
FY25:
138
All amounts in millions USD